Research hub
Everything Stocknote has published on GLP-1: 5 research articles covering 5 companies across 2 categories. The latest piece was published on October 31, 2026.
Lilly’s revenue grew 39% and guidance rose, but two drugs supplied 88% of growth, price fell 15%, and $4.57 a share of acquired R&D held non-GAAP EPS growth to 7%.
CVS Health's Q1 2026 Aetna medical benefit ratio of 84.6% and five consecutive earnings beats confirm the turnaround is structural, not seasonal. Caremark's 11% revenue growth and 200bps GLP-1 share gain are the hidden growth engine.
Conagra's 11% dividend yield is pricing in a B&G Foods-style halving — but Conagra runs at 3.8x leverage versus B&G's 6-8x, and Q3 organic sales just returned to growth led by Frozen and Snacks.
Pfizer's April 2026 patent settlements quietly pushed the Vyndaqel franchise cliff from 2029 to mid-2031 — while a 39%-growing Padcev franchise and a hidden obesity option in Metsera remain priced near zero. The market hasn't caught up.
Hershey trades at 19x forward earnings versus a 10-year median of 26x, while consensus prices in three demonstrably wrong assumptions about cocoa, GLP-1s, and Salty Snacks. The forensic case points to $235 in 12 months and $275+ longer term. Option 2 — Contrarian hook The market thinks GLP-1s will hurt chocolate demand — peer-reviewed Cornell data shows the opposite. Combined with the cocoa hedge lag and an unmodeled Salty Snacks asset, Hershey's mispricing is measurable, falsifiable, and worth 25%+ upside.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
